P23 Oral cyclophosphamide pulse therapy revisited
نویسندگان
چکیده
منابع مشابه
Pulse intravenous cyclophosphamide therapy in pemphigus.
BACKGROUND Adjuvant therapy is commonly used in pemphigus to mitigate the high morbidity and mortality associated with the use of corticosteroids and improve disease control. However, these adjuvant agents are not without adverse effects of their own, including an increased risk of malignancy with the use of oral immunosuppressives. Intravenous pulse cyclophosphamide, which may be more efficaci...
متن کاملCyclophosphamide pulse therapy in idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a progressive disorder with poor prognosis. Response to treatment is infrequent and the use of immunosuppressive agents other than corticosteroids is the subject of ongoing discussion because of uncertain efficacy and side-effects. To determine the efficacy and safety of cyclophosphamide pulse therapy in IPF, this study retrospectively analysed 18 patients...
متن کاملDexamethasone-cyclophosphamide pulse therapy in pemphigus.
Fifty patients with pemphigus (45 pemphigus vulgaris, 5 pemphigus foliaceus) were treated with dexamethasone-cyclophosphamide pulse therapy. The pulse consisted of 136 mg dexamethasone dissolved in 5% dextrose given in a drip over a period of 1-2 hours on 3 consecutive days. In addition, 500 mg cyclophosphamide was added in the drip on the first day. Such pulses were given at monthly intervals....
متن کامل[Cyclophosphamide pulse therapy for refractory rheumatic diseases].
We studied the efficacy of cyclophosphamide pulse therapy (CYP) for refractory rheumatic diseases except for lupus nephritis. Thirty-five patients were included in all, that is 9 patients with systemic lupus erythematosus (SLE), 10 with rheumatoid arthritis (RA), 7 with polymyositis/dermatomyositis (PM/DM), 2 with progressive systemic sclerosis (PSS), 2 with anti-phospholipid antibody syndrome ...
متن کاملSystemic sclerosis and dexamethasone cyclophosphamide pulse therapy.
Sir, There have been quite a few instances where the physician or may be even a dermatologist (mis) advices a patient having systemic sclerosis that there is no satisfactory treatment for this disease, as has also been done in the paper Therapeutic trials for systemic sclerosis: An update by Sardana and Garg.[1] Such patients often feel frustrated and disappointed, till another dermatologist ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Rheumatology
سال: 2011
ISSN: 0973-3698
DOI: 10.1016/s0973-3698(11)60133-7